Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project

Conditions

• Mucormycosis

Eligibility Criteria

Sex

ALL

Age

18 Years - 100 Years

Healthy Volunteers

Not accepted

Interventions

• Mucormycosis — BEHAVIORAL
  Tell the study team about any symptoms or side effects you have, follow study directions, and come to all study appointments (or contact the study team to reschedule).

Study Details

To collect data and samples from participants with cancer who also have invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infection.

Key Dates

Start date

Sep 30, 2025

Status verified

Sep 2025

Primary completion

Dec 31, 2030

Completion

Dec 31, 2032

Study Design

Enrollment

300 participants (estimated)

Arms

• Arm: Group M
  Patients with mucormycosis undergo collection of blood, tissue and BAL fluid samples as well as have their medical records reviewed on study.
• Arm: Group A
  Patients with mucormycosis undergo collection of blood, tissue and BAL fluid samples as well as have their medical records reviewed on study.
• Arm: Group B
  Patients with mucormycosis undergo collection of blood, tissue and BAL fluid samples as well as have their medical records reviewed on study.
• Arm: Group C
  Patients with mucormycosis undergo collection of blood, tissue and BAL fluid samples as well as have their medical records reviewed on study.

Primary Outcome Measure

Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year. ]

Central Contacts

• Dimitrios Kontoyiannis, MD
  (713) 792-0826
  [email protected]

Locations (1)

Find similar trials in Houston, TX